Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trialHugo Ford, Janet Dunn, Fareeda Y. Coxon et al.|The Lancet Oncology|2013Cited by 604
COUGAR-02: A randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma.Hugo Ford, Janet Dunn, Andrea Marshall et al.|Journal of Clinical Oncology|2013Cited by 32